120 related articles for article (PubMed ID: 8495279)
21. A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus deflazacort.
LoCascio V; Ballanti P; Milani S; Bertoldo F; LoCascio C; Zanolin EM; Bonucci E
Calcif Tissue Int; 1998 Mar; 62(3):199-204. PubMed ID: 9501951
[TBL] [Abstract][Full Text] [Related]
22. In vitro improvement of chlorambucil-induced cytotoxicity by deflazacort and 6-methylprednisolone in B-cell chronic lymphocytic leukaemia.
Morabito F; Callea I; Irrera G; Cartisano G; Dattola A; Rodinò A; Brugiatelli M
Eur J Haematol; 1997 May; 58(5):301-6. PubMed ID: 9222284
[TBL] [Abstract][Full Text] [Related]
23. Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study.
Reitter B
Brain Dev; 1995; 17 Suppl():39-43. PubMed ID: 8882570
[TBL] [Abstract][Full Text] [Related]
24. Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation.
Broyer M; Guest G; Gagnadoux MF
J Pediatr; 1992 May; 120(5):721-5. PubMed ID: 1578306
[TBL] [Abstract][Full Text] [Related]
25. Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens.
Di Munno O; Imbimbo B; Mazzantini M; Milani S; Occhipinti G; Pasero G
J Rheumatol; 1995 Aug; 22(8):1492-8. PubMed ID: 7473472
[TBL] [Abstract][Full Text] [Related]
26. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure.
Rutter MM; Collins J; Rose SR; Woo JG; Sucharew H; Sawnani H; Hor KN; Cripe LH; Wong BL
Neuromuscul Disord; 2012 Dec; 22(12):1046-56. PubMed ID: 22967789
[TBL] [Abstract][Full Text] [Related]
27. Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study.
Saviola G; Abdi Ali L; Shams Eddin S; Coppini A; Cavalieri F; Campostrini L; Sacco S; Bucci M; Cirino G; Rossini M
Rheumatology (Oxford); 2007 Jun; 46(6):994-8. PubMed ID: 17384176
[TBL] [Abstract][Full Text] [Related]
28. Prednisone versus deflazacort in the treatment of autoimmune thrombocytopenic purpura: evaluation of clinical response and immunological modifications.
Ferrari A; Pasqualetti D; Del Bianco P; Gandolfo GM; Chistolini A; Mazzucconi MG
Haematologica; 1991; 76(4):342-5. PubMed ID: 1794742
[TBL] [Abstract][Full Text] [Related]
29. Therapy with a new glucocorticoid: effect of deflazacort on linear growth and growth hormone secretion in renal transplantation.
Ferraris JR; Pasqualini T
J Rheumatol Suppl; 1993 Apr; 37():43-6. PubMed ID: 8501752
[TBL] [Abstract][Full Text] [Related]
30. Deflazacort vs prednisone. Effect on blood glucose control in insulin-treated diabetics.
Bruno A; Cavallo-Perin P; Cassader M; Pagano G
Arch Intern Med; 1987 Apr; 147(4):679-80. PubMed ID: 3827456
[TBL] [Abstract][Full Text] [Related]
31. Deflazacort in giant cell arteritis.
Devogelaer JP; Gennari C
J Rheumatol; 2002 Oct; 29(10):2244-5. PubMed ID: 12375347
[No Abstract] [Full Text] [Related]
32. Long versus standard initial steroid therapy for children with the nephrotic syndromeA report from the Southwest Pediatric Nephrology Study Group.
Lande MB; Gullion C; Hogg RJ; Gauthier B; Shah B; Leonard MB; Bonilla-Felix M; Nash M; Roy S; Strife CF; Arbus G
Pediatr Nephrol; 2003 Apr; 18(4):342-6. PubMed ID: 12700959
[TBL] [Abstract][Full Text] [Related]
33. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
[TBL] [Abstract][Full Text] [Related]
34. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis.
Lai HC; FitzSimmons SC; Allen DB; Kosorok MR; Rosenstein BJ; Campbell PW; Farrell PM
N Engl J Med; 2000 Mar; 342(12):851-9. PubMed ID: 10727589
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment.
Wong BL; Rybalsky I; Shellenbarger KC; Tian C; McMahon MA; Rutter MM; Sawnani H; Jefferies JL
J Pediatr; 2017 Mar; 182():296-303.e1. PubMed ID: 28043681
[TBL] [Abstract][Full Text] [Related]
36. Effects of prednisone and deflazacort on vertebral bone mass.
Gennari C; Imbimbo B
Calcif Tissue Int; 1985 Dec; 37(6):592-3. PubMed ID: 3937579
[TBL] [Abstract][Full Text] [Related]
37. Long-term therapy with the new glucocorticosteroid deflazacort in rheumatoid arthritis. Double-blind controlled randomized 12-months study against prednisone.
Eberhardt R; Krüger K; Reiter W; Gross W; Zwingers T
Arzneimittelforschung; 1994 May; 44(5):642-7. PubMed ID: 8024639
[TBL] [Abstract][Full Text] [Related]
38. [Study of lymphocyte subpopulations in chronic autoimmune inflammatory rheumatic diseases. II. Polymyalgia rheumatica: behaviour of lymphocyte subpopulations during treatment with two different corticosteroids].
Coaccioli S; Pinoca F; Giuliani M; Sabatini C; Puxeddu A
Minerva Med; 2005 Oct; 96(5):379-87. PubMed ID: 16227953
[TBL] [Abstract][Full Text] [Related]
39. A randomized study comparing deflazacort and prednisone in heart transplant patients.
Arizón JM; Anguita M; Vallés F; López-Rubio F; López-Granados A; Casares J; Segura J; Mesa D; Muñoz I; Alados P
J Heart Lung Transplant; 1993; 12(5):864-8. PubMed ID: 8241229
[TBL] [Abstract][Full Text] [Related]
40. Deflazacort: a glucocorticoid with few metabolic adverse effects but important immunosuppressive activity.
Gonzalez-Perez O; Luquin S; Garcia-Estrada J; Ramos-Remus C
Adv Ther; 2007; 24(5):1052-60. PubMed ID: 18029332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
